#	Pagina
attuale pagina	/open-h2020/projects/225353/index.html

Opendata, web and dolomites

DERMAREP SIGNED

Clinical validation and production upscaling of a novel product for healing of Pressure Ulcers, Leg Ulcers and Diabetic Foot Ulcers.

Total Cost €

EC-Contrib. €

Partnership

Views

DERMAREP project word cloud

Explore the words cloud of the DERMAREP project. It provides you a very rough idea of what is the project "DERMAREP" about.

period 50bn aging pep dressing burden expensive standard 41bn lu foot patients orderly readily wound decades pus 2015 dfu 2020 healing establishing disorders time membrane proceeded protein collagen pain severe eggshell metabolic mobility months lus 53bn disruptive complicated benchmark reparative form hydrocolloid integrity trade anatomic 56bn driver purified pressure countries global leg esm innovative foam pu distress soc ulcer least biomaterial egg soa significantly dressings silicon 52bn isolation chronic population failed 47bn social wounds care treatment sustained industry unhealed emotional dfus physical heal dermarep market diabetic healthcare repair relatively diabetes functional

Project "DERMAREP" data sheet

The following table provides information about the project.

Coordinator	BIOVOTEC AS Organization address address: HOFFSVEIEN 21 23 city: OSLO postcode: 275 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Norway [NO]
Total cost	4˙284˙339 €
EC max contribution	2˙999˙037 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-10-01 to 2021-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BIOVOTEC AS BIOVOTEC AS Organization address address: HOFFSVEIEN 21 23 city: OSLO postcode: 275 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (OSLO)	coordinator	886˙000.00
2	CROMSOURCE SRL CROMSOURCE SRL Organization address address: VIA GIORGIO DE SANDRE 3 city: VERONA VR postcode: 37135 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (VERONA VR)	participant	1˙587˙687.00
3	ADHEXPHARMA ADHEXPHARMA Organization address address: RUE DE LUBECK 30 city: PARIS postcode: 75016 website: www.plastopharma.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	525˙350.00

Map

Project objective

A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity within a period of 3 months or that has proceeded through the repair process without establishing a sustained and anatomic and functional result. Chronic wounds may require several years to heal, and some remain unhealed for decades. During this time, patients can experience severe pain, significant emotional and physical distress, reduced mobility and social isolation.

LU, PU and DFU are a major healthcare cost for all developed countries. The main driver for growth in cost is the treatment of chronic and complex wounds in the aging population, complicated by the increase in diabetes and other metabolic disorders. LUs account for $50Bn of global wound care burden in 2015 and are to reach $53Bn in 2020. DFUs account for $52Bn – and are to reach $56Bn by 2020. Further, PUs account for $41Bn of global wound care burden in 2015 – and are to reach $47Bn by 2020.

We have developed an innovative wound dressing, DermaRep™, that is based on biomaterial derived from Eggshell Membrane (ESM) – a by-product readily available in the egg industry. The purified form of ESM is called Purified Eggshell Membrane Protein (PEP).

DermaRep™ is disruptive and will become the benchmark in the wound healing market as it directly addresses the healthcare needs by providing a novel wound care product that is significantly more effective than current Standard of Care (SoC, relatively non-expensive silicon, foam and hydrocolloid dressings) and at least as effective as existing State of the Art (SoA) collagen-based dressings.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DERMAREP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DERMAREP" are provided by the European Opendata Portal: CORDIS opendata.